Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303)

Reviewer: Christopher Dolinsky, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 2 de junio del 2007

Translation for this article does not exist